BridgeBio Pharma (BBIO) Change in Receivables (2024 - 2026)

BridgeBio Pharma (BBIO) has 3 years of Change in Receivables data on file, last reported at $65.8 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Receivables fell 40.49% year-over-year to $65.8 million; the trailing twelve-month figure through Mar 2026 stood at $90.0 million (up 174.82% YoY), and the FY2025 full-year result was $134.7 million, up 4434.57% from the prior year.
• Change in Receivables advanced to $65.8 million in Q1 2026, from $22.9 million in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $233.7 million in Q1 2024 to a low of -$234.8 million in Q2 2024.
• A 3-year average of $22.6 million and a median of $22.9 million in 2025 frame the typical range for Change in Receivables.
• Peak annual rise in Change in Receivables reached 21885.71% in 2025, while the deepest fall reached 52.71% in 2025.
• Tracing BBIO's Change in Receivables over 3 years: stood at $4.2 million in 2024, then soared by 440.2% to $22.9 million in 2025, then surged by 186.93% to $65.8 million in 2026.
• Business Quant data shows BBIO's Change in Receivables at $65.8 million in Q1 2026, $22.9 million in Q4 2025, and $39.6 million in Q3 2025.